Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$16.22
+3.2%
$11.93
$7.08
$17.18
$325.31M0.7181,484 shs170,121 shs
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$0.55
-0.2%
$0.55
$0.22
$1.97
$30.32M1.031.82 million shs260 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.43
+3.0%
$3.28
$2.23
$4.13
$165.27M1.29417,158 shs374,468 shs
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$8.00
-5.1%
$7.69
$5.67
$30.60
$139.40M-0.11164,562 shs71,210 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
+3.25%+28.73%+39.83%+83.48%+17.88%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
0.00%0.00%0.00%0.00%-53.07%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
+3.00%+2.39%+3.00%+17.06%+5.21%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-5.10%+7.53%+11.93%-14.53%-67.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amarin Corporation PLC stock logo
AMRN
Amarin
0.7348 of 5 stars
0.55.00.00.03.20.00.6
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
2.2601 of 5 stars
3.20.00.04.20.61.70.6
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
4.2415 of 5 stars
3.52.00.00.02.64.23.1
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
4.2089 of 5 stars
3.23.00.04.22.01.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.00
Sell$12.00-26.02% Downside
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
2.40
Hold$3.92613.29% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00104.08% Upside
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.33
Hold$24.00200.00% Upside

Current Analyst Ratings Breakdown

Latest MRNS, RAPT, PBYI, and AMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Amarin Corporation PLC stock logo
AMRN
Amarin
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$7.00 ➝ $12.00
5/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.00
5/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$48.00
4/17/2025
Amarin Corporation PLC stock logo
AMRN
Amarin
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$20.00 ➝ $7.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$228.61M1.47N/AN/A$23.62 per share0.69
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$30.99M0.98N/AN/A$0.31 per share1.77
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.50M0.74$0.88 per share3.91$1.88 per share1.82
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$1.53M86.48N/AN/A$11.51 per share0.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$82.18M-$3.64N/AN/AN/A-41.07%-17.21%-12.16%7/30/2025 (Estimated)
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$30.28M$0.774.459.03N/A16.37%49.35%18.25%7/30/2025 (Estimated)
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$129.87M-$19.20N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)

Latest MRNS, RAPT, PBYI, and AMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$2.48-$0.64+$1.84-$0.08N/AN/A
5/7/2025Q1 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.53
2.55
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/A
1.66
1.47
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.11
1.53
1.43
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/A
21.11
21.11

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
98.80%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
99.09%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
1.96%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
5.46%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.30%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
6.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36020.71 million20.30 millionOptionable
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
11055.22 million52.20 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million38.07 millionOptionable
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
8016.54 million15.45 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$16.22 +0.51 (+3.25%)
As of 06/30/2025 04:00 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Marinus Pharmaceuticals stock logo

Marinus Pharmaceuticals NASDAQ:MRNS

$0.55 0.00 (-0.16%)
As of 02/11/2025

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.43 +0.10 (+3.00%)
As of 06/30/2025 04:00 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Rapt Therapeutics stock logo

Rapt Therapeutics NASDAQ:RAPT

$8.00 -0.43 (-5.10%)
As of 06/30/2025 04:00 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company